Mylan (MYL)
News
| May 29 | Mylan, Sunovion Settle Patent Dispute |
| May 29 | Mylan starts selling generic Lipitor in the US |
| May 29 | Mylan (MYL) Launches Generic Version of Lipitor Street Insider |
| May 29 | $MYL Launches Generic Version of Lipitor by Benzinga |
| May 29 | Mylan Launches Generic Version of Lipitor Benzinga |
| May 29 | Mylan Launches Generic Version of Lipitor® PR Newswire |
| May 29 | Mylan, Sunovion reach agreement on lawsuit |
| May 29 | UPDATE 1-Mylan settles patent suit with Dainippon Sumitomo unit |
| May 29 | S&P 500 Analyst Target Price Changes for May 29 |
| May 29 | Mylan announces settlement agreement erlated to generic Xopenex |
| May 25 | $MYL by shirleyteh |
| May 25 | $myl by shirleyteh |
| May 24 | $TARO holders sign this online petition if u agree->http://stks.co/3yVp will be sent to BOD $TEVA $EIS $AISHX $PRGO $MYL $PFE by imhobutdydd |
| May 23 | Watch $MYL at the 200ma .Might consider buying if it bounces today. by AltecBX |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Drugs - Generic
Mylan Inc. is a global generic and specialty pharmaceuticals company headquartered in Canonsburg, Pennsylvania. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third largest generic and pharmaceuticals company in the U.S. to the third largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 18,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing of more than 45 billion doses.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Mylan is down 7.95% over the last year vs S&P 500 Total Return up 2.32%, Watson Pharmaceuticals up 13.25%, and Warner Chilcott down 19.15%.
- MYL Total Returns
- ^SPXTR Total Returns
- WPI Total Returns
- WCRX Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these MYL related companies
Pro Strategies Featuring MYL
Did Mylan make it into our Pro Portfolio Strategies?
MYL Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other MYL Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MYL | 21.53 | -0.36 | -1.64% | 9.345B |
| MYJ | 16.13 | -0.14 | -0.86% | |
| MYGN | 24.98 | -0.22 | -0.87% | 2.124B |
| MYF | 15.96 | -0.14 | -0.87% | |
| MYC | 16.30 | +0.01 | +0.06% | |
| MY | 1.38 | -0.14 | -9.21% | 190.00M |
| MXWL | 6.46 | -0.60 | -8.50% | 199.16M |
| MXT | 1.15 | -0.03 | -2.54% | 40.67M |
| MVIS | 1.91 | -0.68 | -26.25% | 44.08M |
| MVG | 8.07 | +0.10 | +1.25% | 443.69M |
